Comparative Pharmacology
Head-to-head clinical analysis: ATAZANAVIR SULFATE versus ATAZANAVIR SULFATE RITONAVIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATAZANAVIR SULFATE versus ATAZANAVIR SULFATE RITONAVIR.
ATAZANAVIR SULFATE vs ATAZANAVIR SULFATE; RITONAVIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atazanavir is an azapeptide HIV-1 protease inhibitor. It selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, preventing formation of mature virions.
Atazanavir is an azapeptide HIV-1 protease inhibitor that inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, preventing formation of mature virions. Ritonavir is an HIV protease inhibitor that also inhibits CYP3A, boosting atazanavir levels.
300 mg orally once daily with ritonavir 100 mg orally once daily, or 400 mg orally once daily without ritonavir (when used alone).
Atazanavir 300 mg with ritonavir 100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: ~6.5 to 7 hours; supports once-daily dosing.
Atazanavir: ~6.5-7 hours (when boosted with ritonavir). Ritonavir: ~3-5 hours. Clinical context: Atazanavir requires ritonavir boosting to achieve therapeutic trough concentrations; once-daily dosing maintains efficacy.
Biliary/fecal: ~79% as unchanged drug; renal: ~13% (including <1% unchanged).
Biliary/fecal (major route): atazanavir 79% as unchanged drug, 13% as metabolites; ritonavir 86.4% as metabolites, 3.5% unchanged. Renal: atazanavir 7% (20% as unchanged); ritonavir 11.3% (3.5% unchanged).
Category C
Category A/B
Protease Inhibitor
Protease Inhibitor